Search
Cidofovir
go.drugbank.com/drugs/DB00369ApprovedInvestigational[FDA label] It was manufactured by _Gilead_ and initially approved by the FDA in 1996, but has since been discontinued.[L6223]
Temazepam
go.drugbank.com/drugs/DB00231ApprovedUnfortunately, however, given its frequent use and the inherent nature of its pharmacological effects, temazepam - like many other benzodiazepines - possesses a high potential for misuse and is genuinely … In particular, before temazepam saw regular prescription use in civilians it was - and still is - employed by the US military as a sedative-hypnotic medication to be taken by soldiers, pilots, etc. to
Maraviroc
go.drugbank.com/drugs/DB04835ApprovedInvestigationalIt was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007. … Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the
Pitolisant
go.drugbank.com/drugs/DB11642ApprovedInvestigational[A32025] About 60-70% of patients with narcolepsy experience cataplexy, which is a sudden loss of muscle tone triggered by positive or negative emotions. … Commonly marketed under the trade name Wakix, oral pitolisant was approved by the EMA in 2016 [A183062] for the treatment of narcolepsy with or without cataplexy.
Darolutamide
go.drugbank.com/drugs/DB12941ApprovedInvestigational[A189054,A189063] Darolutamide was developed by Bayer HealthCare Pharmaceuticals Inc. and approved by the FDA on July 30th, 2019.[L10887] … The goal of treatment with darolutamide is to delay the progression of prostate cancer to metastatic disease, increasing quality of life and life expectancy for those with advanced prostate cancer.
Vaborbactam
go.drugbank.com/drugs/DB12107ApprovedInvestigationalVaborbactam is added to the therapy to reduce the extent meropenem degradation by inhibiting the serine beta-lactamases expressed by the microorganism of target. … In August 2017, a combination antibacterial therapy under the market name Vabomere was approved by the FDA for the treatment of adult patients with complicated urinary tract infections (cUTI).
Islatravir
go.drugbank.com/drugs/DB15653ApprovedInvestigational[A275492, L56138] Chemically, it is a deoxyadenosine analogue distinguished by a 4'-ethynyl group and a 2-fluoro substitution, which collectively enhance its metabolic stability and potency. … [A275490, A275492] Because it is a substrate for deoxycytidine kinase (dCK), its efficacy can be compromised by co-administration with other dCK substrates like lamivudine or emtricitabine, which are consequently
Azacitidine
go.drugbank.com/drugs/DB00928ApprovedInvestigational[A1415] The use of oral azacitidine for the treatment of AML in patients in complete remission was approved by the FDA in September 2020.[L35335] … It differs from cytosine by the presence of nitrogen in the C5-position, key in its hypomethylating activity.[A1406,A1413,A1415] Two main mechanisms of action have been proposed for azacitidine.
Leflunomide
go.drugbank.com/drugs/DB01097ApprovedInvestigationalLeflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.
Ethchlorvynol
go.drugbank.com/drugs/DB00189ApprovedIllicitWithdrawnIt has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists.